Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;36(1):175-181.
doi: 10.3904/kjim.2019.104. Epub 2020 Mar 30.

Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma

Hyerim Ha  1   2 , Bhumsuk Keam  1   3 , Chan-Young Ock  1 , Tae Min Kim  1   3 , Jin Ho Kim  4 , Eun-Jae Chung  5 , Seong Keun Kwon  5 , Soon-Hyun Ahn  5 , Hong-Gyun Wu  4 , Myung-Whun Sung  5 , Dae Seog Heo  1   3
Affiliations

Role of concurrent chemoradiation on locally advanced unresectable adenoid cystic carcinoma

Hyerim Ha et al. Korean J Intern Med. 2021 Jan.

Abstract

Background/aims: Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor characterized by indolence, with a high rate of local recurrence and distant metastasis. This study aimed to investigate the effect of concurrent chemoradiation (CCRT) on locally advanced unresectable ACC.

Methods: We retrospectively analyzed clinical data from 10 patients with pathologically confirmed ACC of the head and neck who received CCRT with cisplatin in Seoul National University Hospital between 2013 and 2018.

Results: Ten patients with unresectable disease at the time of diagnosis or with positive margins after surgical resection received CCRT with weekly cisplatin. Eight patients (80%) achieved complete remission, of which three later developed distant metastases without local relapse; one patient developed distant metastasis and local relapse. Two patient achieved partial remission without progression. Patients experienced several toxicities, including dry mouth, radiation dermatitis, nausea, and salivary gland inflammation of mostly grade 1 to 2. Only one patient showed grade 3 oral mucositis. Median relapse-free survival was 34.5 months (95% confidence interval, 22.8 months to not reached).

Conclusion: CCRT with cisplatin is effective for local control of ACC with manageable toxicity and may be an effective treatment option for locally advanced unresectable ACC.

Keywords: Carcinoma, adenoid cystic; Chemoradiotherapy; Cisplatin.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1.
Figure 1.
Representative image before and after concurrent chemoradiation. (A) Patient No. 1: light parotid gland mass disappeared after concurrent chemoradiotherapy (CCRT). (B) Patient No. 6: adenoid cystic carcinoma of maxillary sinus disappeared after CCRT.
Figure 2.
Figure 2.
Relapse-free survival after concurrent chemoradiation. RFS, relapse-free survival; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8:177–184. - PubMed
    1. Leeming R, Jenkins M, Mendelsohn G. Adenoid cystic carcinoma of the breast. Arch Surg. 1992;127:233–235. - PubMed
    1. Bennett AK, Mills SE, Wick MR. Adenoid cystic carcinoma of the lung. Pathol Case Rev. 2004;9:253–258.
    1. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 1974;128:512–520. - PubMed
    1. Ju J, Li Y, Chai J, et al. The role of perineural invasion on head and neck adenoid cystic carcinoma prognosis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:691–701. - PubMed

Publication types

LinkOut - more resources